RIPK4 was shown to activate the CRAF-MEK-ERK pathway by promoting the degradation of proteasome-mediated phosphatidylethanolamine binding protein 1 (PEBP1) in pancreatic cancer [190]. Here, RAF1 is linked to pancreatic neoplasm.